Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
JANX
JANX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JANX News
VERAXA Biotech Secures $27.5 Million Financing Agreement
May 28 2026
Yahoo Finance
Prosight Management Increases Stake in Nektar Therapeutics
May 23 2026
Yahoo Finance
Janux Therapeutics Q1 Earnings Beat Expectations Despite Revenue Miss
May 07 2026
seekingalpha
Janux Discontinues JANX008 Development to Focus on Other Pipeline Programs
Apr 27 2026
stocktwits
Janux Therapeutics Discontinues JANX008 Program
Apr 27 2026
seekingalpha
Oil Price Surge Leads to Market Decline
Apr 20 2026
NASDAQ.COM
Janux Therapeutics Reports Increased Q4 Losses
Feb 27 2026
NASDAQ.COM
Janux Therapeutics Q4 Earnings Beat Expectations
Feb 26 2026
seekingalpha
Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement
Jan 22 2026
Benzinga
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development
Jan 22 2026
stocktwits
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for $50M Collaboration on Solid Tumor Therapy
Jan 22 2026
NASDAQ.COM
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million
Jan 22 2026
seekingalpha
Janux Completes Phase 1a Trial for JANX008, Initiates Expansion Cohorts
Dec 24 2025
NASDAQ.COM
Janux Initiates Expansion Phase for JANX008 Clinical Trial Targeting EGFR
Dec 23 2025
Businesswire
Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise
Dec 04 2025
NASDAQ.COM
Stifel Continues to Recommend Buy for Janux Therapeutics (JANX)
Dec 03 2025
NASDAQ.COM
Show More News
